Submit PSUR data: CDSCO Panel Tells Shilpa on additional indication of Rheumatoid Arthritis drug Adalimumab

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2023-12-30 11:30 GMT | Update On 2024-03-22 17:14 GMT

New Delhi: In response to the proposal presented by the drug major Shilpa for the extrapolation of indications for Adalimumab 100mg/mL approved in India for the indication of Rheumatoid Arthritis (RA) in adult patients, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has recommended the firm to submit periodic safety update report (PSUR) data for the first six months for consideration of approval for the additional indications.

This came after the firm presented the proposal for extrapolation of indications in line with the innovator-approved indications for Adalimumab 100mg/mL approved in India for the indication of Rheumatoid Arthritis (RA) in adult patients.

The committee noted that the firm has recently launched the drug product in the market and has not yet submitted the first PSUR.

Adalimumab injection products are in a class of medications called tumor necrosis factor (TNF) inhibitors. They work by blocking the action of TNF, a substance in the body that causes inflammation.

Adalimumab is a type of drug known as a biological therapy. In rheumatoid arthritis and some other conditions, too much of a protein called TNF is produced in the body. This causes inflammation, pain, and damage to your joints.

Adalimumab is the first fully human recombinant immunoglobulin G1 monoclonal antibody that binds and neutralizes soluble and membrane-bound tumor necrosis factor (TNF) so that it cannot interact with p55 and p75 cell-surface TNF receptors.

At the recent SEC meeting for analgesic and rheumatology held on 8th and 9th November 2023, the expert panel reviewed the proposal for extrapolation of indications in line with the innovator-approved indications for Adalimumab 100mg/mL approved in India for the indication of Rheumatoid Arthritis (RA) in adult patients presented by drug major Shilpa.

After detailed deliberation, the committee recommended that the firm should submit PSUR data for the first six months for consideration of approval for the additional indications.

Also Read:Ajanta Pharma Gets CDSCO Panel Nod To Study Antihypertensive FDC

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Submit PSUR data: CDSCO Panel Tells Shilpa on additional indication of Rheumatoid Arthritis drug Adalimumab

Similar News

Sanofi Rilzabrutinib earns orphan designation in EU for IgG4 related disease

Novo Nordisk Launches Wegovy in South Africa, Ramping Up Obesity Drug Battle with Eli Lilly

Lupin to Conduct BE Study for Synthetic Semaglutide Tablets in 3 Strengths

Sun Pharma Gets CDSCO Panel Nod for Active PMS of Fexuprazan Hydrochloride Tablets

Chemists' Body Warns of 55% Rise in Drug Abuse, Calls for Ban on 10-Minute Prescription Drug Delivery

Cohance Lifesciences announces USD 10 mn investment in cGMP Bioconjugation Suite at NJ Bio

Bayer, Kumquat Biosciences ink pact to develop, commercialize KRAS G12D inhibitor

Setback to Torrent: CDSCO Panel Rejects Phase III Waiver Plea for Prucalopride Over Safety Data Gaps